{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:28:37Z","timestamp":1780522117809,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04469-1","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:16:29Z","timestamp":1754392589000},"page":"1249-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin-induced nephrotoxicity: a randomized, triple-blinded, placebo-controlled clinical trial"],"prefix":"10.1007","volume":"399","author":[{"given":"Vahid","family":"Soleimani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozita","family":"Khodashahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Arian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Tavanaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Omidkhoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-1175","authenticated-orcid":false,"given":"Sepideh","family":"Elyasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"4469_CR1","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1080\/07853890.2022.2069854","volume":"54","author":"A Aghemo","year":"2022","unstructured":"Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, Bueverov AO, Drapkina OM, Gillessen A, Kagarmanova EM, Korochanskaya NV, Kucheryavii UA, Lazebnik LB, Livzan MA, Maev IV, Martynov AI, Osipenko MF, Sas EI, Starodubova A, Uspensky YP, Vinnitskaya EV, Yakovenko EP, Yakovlev AA (2022) Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Ann Med 54:1548\u20131560. https:\/\/doi.org\/10.1080\/07853890.2022.2069854","journal-title":"Ann Med"},{"key":"4469_CR2","doi-asserted-by":"publisher","first-page":"105958","DOI":"10.1016\/j.jff.2023.105958","volume":"113","author":"F Arab","year":"2024","unstructured":"Arab F, Yousefi F, Jaafari MR, Rajabian A, Dana H, Tabasi N, Behboodifar S, Faridzadeh A, Mahmoudi M (2024) Evaluation of the immune-modulatory, anti-oxidant, proliferative, and anti-apoptotic effects of nano-silymarin on mesenchymal stem cells isolated from multiple sclerosis patients\u2019 adipose tissue sources. J Funct Foods 113:105958. https:\/\/doi.org\/10.1016\/j.jff.2023.105958","journal-title":"J Funct Foods"},{"key":"4469_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/2042018816638223","volume":"7","author":"O Bamgbola","year":"2016","unstructured":"Bamgbola O (2016) Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab 7:136\u2013147. https:\/\/doi.org\/10.1177\/2042018816638223","journal-title":"Ther Adv Endocrinol Metab"},{"key":"4469_CR4","doi-asserted-by":"publisher","unstructured":"Camini FC, Costa DC (2020) Silymarin: not just another antioxidant. J Basic Clin Physiol Pharmacol 31. https:\/\/doi.org\/10.1515\/jbcpp-2019-0206","DOI":"10.1515\/jbcpp-2019-0206"},{"key":"4469_CR5","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jfda.2018.01.003","volume":"26","author":"YY Cheng","year":"2018","unstructured":"Cheng YY, Hsieh CH, Tsai TH (2018) Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics. J Food Drug Anal 26:S88\u2013S95. https:\/\/doi.org\/10.1016\/j.jfda.2018.01.003","journal-title":"J Food Drug Anal"},{"key":"4469_CR6","doi-asserted-by":"publisher","unstructured":"Contreras-Villamizar K, Barbosa O, Mu\u00f1oz AC, Su\u00e1rez JS, Gonz\u00e1lez CA, Vargas DC, Rodr\u00edguez-S\u00e1nchez MP, Garc\u00eda-Padilla P, Valderrama-Rios MC, Cort\u00e9s JA (2023) Risk factors associated with acute kidney injury in a cohort of hospitalized patients with COVID-19. BMC Nephrol 24:140. https:\/\/doi.org\/10.1186\/s12882-023-03172-8","DOI":"10.1186\/s12882-023-03172-8"},{"key":"4469_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.fct.2013.07.06322","volume":"60","author":"S Cuf\u00ed","year":"2013","unstructured":"Cuf\u00ed S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuy\u00e0s E, Martin-Castillo B, Barraj\u00f3n-Catal\u00e1n E, Visa J, Segura-Carretero A, Bosch-Barrera J, Joven J, Micol V, Menendez JA (2013) Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol 60:360\u2013368. https:\/\/doi.org\/10.1016\/j.fct.2013.07.06322","journal-title":"Food Chem Toxicol"},{"key":"4469_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.18433\/j3f88s","volume":"15","author":"S Dashti-Khavidaki","year":"2012","unstructured":"Dashti-Khavidaki S, Shahbazi F, Khalili H, Lessan-Pezeshki M (2012) Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharm Sci 15:112\u2013123. https:\/\/doi.org\/10.18433\/j3f88s","journal-title":"J Pharm Pharm Sci"},{"key":"4469_CR9","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00210-023-02490-w","volume":"396","author":"PS Delghandi","year":"2023","unstructured":"Delghandi PS, Soleimani V, Fazly Bazzaz BS, Hosseinzadeh H (2023) A review on oxidant and antioxidant effects of antibacterial agents: impacts on bacterial cell death and division and therapeutic effects or adverse reactions in humans. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 396:2667\u20132686. https:\/\/doi.org\/10.1007\/s00210-023-02490-w","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"10","key":"4469_CR10","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1093\/cid\/ciaa1354","volume":"72","author":"TJ Dilworth","year":"2021","unstructured":"Dilworth TJ, Schulz LT, Rose WE (2021) Vancomycin advanced therapeutic drug monitoring: exercise in futility or virtuous endeavor to improve drug efficacy and safety? Clin Infect Dis. 72(10):e675\u2013e681. https:\/\/doi.org\/10.1093\/cid\/ciaa1354","journal-title":"Clin Infect Dis."},{"key":"4469_CR11","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/tox.24223","volume":"39","author":"FM El-Demerdash","year":"2024","unstructured":"El-Demerdash FM, Ahmed MM, El-Sayed RA, Mohemed TM, Gerges MN (2024) Nephroprotective effects of silymarin and its fabricated nanoparticles against aluminum-induced oxidative stress, hyperlipidemia, and genotoxicity. Environ Toxicol 39:3746\u20133759. https:\/\/doi.org\/10.1002\/tox.24223","journal-title":"Environ Toxicol"},{"key":"4469_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","volume":"68","author":"S Elyasi","year":"2012","unstructured":"Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68:1243\u20131255. https:\/\/doi.org\/10.1007\/s00228-012-1259-9","journal-title":"Eur J Clin Pharmacol"},{"key":"4469_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00228-012-1406-3","volume":"69","author":"S Elyasi","year":"2013","unstructured":"Elyasi S, Khalili H, Hatamkhani S, Dashti-Khavidaki S (2013) Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol 69:747\u2013754. https:\/\/doi.org\/10.1007\/s00228-012-1406-3","journal-title":"Eur J Clin Pharmacol"},{"key":"4469_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/ptr.5704","volume":"30","author":"S Elyasi","year":"2016","unstructured":"Elyasi S, Hosseini S, Niazi Moghadam MR, Aledavood SA, Karimi G (2016) Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: a randomized, double-blinded, placebo-controlled clinical trial. Phytother Res: PTR 30:1879\u20131885. https:\/\/doi.org\/10.1002\/ptr.5704","journal-title":"Phytother Res: PTR"},{"key":"4469_CR15","doi-asserted-by":"publisher","unstructured":"Fatemi Shandiz A, Karimi G, Dayyani M, Hosseini S, Elyasi S (2024) Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer. J Oncol Pharm Pract 10781552241268778. https:\/\/doi.org\/10.1177\/10781552241268778","DOI":"10.1177\/10781552241268778"},{"key":"4469_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","volume":"102","author":"EJ Filippone","year":"2017","unstructured":"Filippone EJ, Kraft WK, Farber JL (2017) The nephrotoxicity of vancomycin. Clin Pharmacol Ther 102:459\u2013469. https:\/\/doi.org\/10.1002\/cpt.726","journal-title":"Clin Pharmacol Ther"},{"key":"4469_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/molecules24030653","volume":"24","author":"Z Gai","year":"2019","unstructured":"Gai Z, Samodelov SL, Kullak-Ublick GA, Visentin M (2019) Molecular mechanisms of colistin-induced nephrotoxicity. Molecules (Basel, Switzerland) 24:653. https:\/\/doi.org\/10.3390\/molecules24030653","journal-title":"Molecules (Basel, Switzerland)"},{"key":"4469_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00228-022-03434-8","volume":"79","author":"M Ghodousi","year":"2023","unstructured":"Ghodousi M, Karbasforooshan H, Arabi L, Elyasi S (2023) Silymarin as a preventive or therapeutic measure for chemotherapy and radiotherapy-induced adverse reactions: a comprehensive review of preclinical and clinical data. Eur J Clin Pharmacol 79:15\u201338. https:\/\/doi.org\/10.1007\/s00228-022-03434-8","journal-title":"Eur J Clin Pharmacol"},{"key":"4469_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1080\/01480545.2019.1584208","volume":"43","author":"S Guzel","year":"2020","unstructured":"Guzel S, Sahinogullari ZU, Canacankatan N, Antmen SE, Kibar D, Coskun Yilmaz B (2020) Potential renoprotective effects of silymarin against vancomycin-induced nephrotoxicity in rats. Drug Chem Toxicol 43:630\u2013636. https:\/\/doi.org\/10.1080\/01480545.2019.1584208","journal-title":"Drug Chem Toxicol"},{"key":"4469_CR20","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/nau.23249","volume":"36","author":"SS Hassan","year":"2017","unstructured":"Hassan SS, Thomann C, Ettarh R, Ahmad Z (2017) Possible protective role of silybin against polymyxin E-induced toxic effect in rat kidneys: a biochemical approach. Neurourol Urodyn 36:2003\u20132010. https:\/\/doi.org\/10.1002\/nau.23249","journal-title":"Neurourol Urodyn"},{"key":"4469_CR21","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.phanu.2021.100253","volume":"15","author":"S Hosseini","year":"2021","unstructured":"Hosseini S, Rezaei S, Moghaddam MRN, Elyasi S, Karimi G (2021) Evaluation of oral nano-silymarin formulation efficacy on prevention of radiotherapy induced mucositis: a randomized, double-blinded, placebo-controlled clinical trial. PharmaNutrition 15:100253. https:\/\/doi.org\/10.1016\/j.phanu.2021.100253","journal-title":"PharmaNutrition"},{"key":"4469_CR22","doi-asserted-by":"publisher","first-page":"e20160","DOI":"10.1590\/s2175-97902022e20160","volume":"58","author":"S Javed","year":"2022","unstructured":"Javed S, Kohli K, Ahsan W (2022) Bioavailability augmentation of silymarin using natural bioenhancers: an in vivo pharmacokinetic study. Braz\u00a0J Pharm Sci 58:e20160. https:\/\/doi.org\/10.1590\/s2175-97902022e20160","journal-title":"Braz\u00a0J Pharm Sci"},{"key":"4469_CR23","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/ijms23042052","volume":"23","author":"WC Kan","year":"2022","unstructured":"Kan WC, Chen YC, Wu VC, Shiao CC (2022) Vancomycin-associated acute kidney injury: a narrative review from pathophysiology to clinical application. Int J Mol Sci 23:2052. https:\/\/doi.org\/10.3390\/ijms23042052","journal-title":"Int J Mol Sci"},{"key":"4469_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ptr.6231","volume":"33","author":"H Karbasforooshan","year":"2019","unstructured":"Karbasforooshan H, Hosseini S, Elyasi S, Fani Pakdel A, Karimi G (2019) Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res: PTR 33:379\u2013386. https:\/\/doi.org\/10.1002\/ptr.6231","journal-title":"Phytother Res: PTR"},{"key":"4469_CR25","first-page":"308","volume":"14","author":"G Karimi","year":"2011","unstructured":"Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M (2011) \u201cSilymarin\u201d, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 14:308\u2013317","journal-title":"Iran J Basic Med Sci"},{"key":"4469_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03372-5","author":"A Karimian","year":"2024","unstructured":"Karimian A, Karimzadeh I, Shafiekhani M, Heidari R, Masjedi F, Izadi F, Barshan-Tashnizi N, Kane-Gill SL, Mahmoudi L (2024) Protective effects of silymarin on preventing vancomycin nephrotoxicity in infectious patients: a randomized, double-blinded, placebo-controlled, pilot clinical trial. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03372-5","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"4469_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/MCC.0000000000001099","volume":"29","author":"I Karimzadeh","year":"2023","unstructured":"Karimzadeh I, Strader M, Kane-Gill SL, Murray PT (2023) Prevention and management of antibiotic associated acute kidney injury in critically ill patients: new insights. Curr Opin Crit Care 29:595\u2013606. https:\/\/doi.org\/10.1097\/MCC.0000000000001099","journal-title":"Curr Opin Crit Care"},{"key":"4469_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/FTD.0000000000001075","volume":"45","author":"AS Lim","year":"2023","unstructured":"Lim AS, Foo SHW, Benjamin Seng JJ, Magdeline Ng TT, Chng HT, Han Z (2023) Area-under-curve-guided versus trough-guided monitoring of vancomycin and its impact on nephrotoxicity: a systematic review and meta-analysis. Ther Drug Monit 45:519\u2013532. https:\/\/doi.org\/10.1097\/FTD.0000000000001075","journal-title":"Ther Drug Monit"},{"key":"4469_CR29","first-page":"85","volume":"37","author":"K Makris","year":"2016","unstructured":"Makris K, Spanou L (2016) Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev 37:85\u201398","journal-title":"Clin Biochem Rev"},{"key":"4469_CR30","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1007\/s11033-020-05635-9","volume":"47","author":"N Malkani","year":"2020","unstructured":"Malkani N, Naeem A, Ijaz F, Mumtaz S, Ashraf S, Sohail MI (2020) Silybum marianum (milk thistle) improves vancomycin induced nephrotoxicity by downregulating apoptosis. Mol Biol Rep 47:5451\u20135459. https:\/\/doi.org\/10.1007\/s11033-020-05635-9","journal-title":"Mol Biol Rep"},{"key":"4469_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/10781552211006182","volume":"28","author":"GSA Moezian","year":"2022","unstructured":"Moezian GSA, Javadinia SA, Sales SS, Fanipakdel A, Elyasi S, Karimi G (2022) Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: a randomized, triple blind, placebo-controlled clinical trial. J Oncol Pharm Pract 28:827\u2013835. https:\/\/doi.org\/10.1177\/10781552211006182","journal-title":"J Oncol Pharm Pract"},{"key":"4469_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medicina54010001","volume":"54","author":"M Mombeini","year":"2018","unstructured":"Mombeini M, Saki G, Khorsandi L, Bavarsad N (2018) Effects of silymarin-loaded nanoparticles on HT-29 human colon cancer cells. Medicina (Kaunas, Lithuania) 54:1. https:\/\/doi.org\/10.3390\/medicina54010001","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"4469_CR33","doi-asserted-by":"publisher","first-page":"OC11","DOI":"10.7860\/jcdr\/2015\/12776.5789","volume":"9","author":"A Momeni","year":"2015","unstructured":"Momeni A, Hajigholami A, Geshnizjani S, Kheiri S (2015) Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study. J Clin Diagn Res 9:OC11-13. https:\/\/doi.org\/10.7860\/jcdr\/2015\/12776.5789","journal-title":"J Clin Diagn Res"},{"key":"4469_CR34","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/molecules24091688","volume":"24","author":"V Piazzini","year":"2019","unstructured":"Piazzini V, D\u2019Ambrosio M, Luceri C, Cinci L, Landucci E, Bilia AR, Bergonzi MC (2019) Formulation of nanomicelles to improve the solubility and the oral absorption of silymarin. Molecules (Basel, Switzerland) 24:1688","journal-title":"Molecules (Basel, Switzerland)"},{"key":"4469_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/2008-7802.174762","volume":"7","author":"Z Sedighifard","year":"2016","unstructured":"Sedighifard Z, Roghani F, Bidram P, Harandi SA, Molavi S (2016) Silymarin for the prevention of contrast-induced nephropathy: a placebo-controlled clinical trial. Int J Prev Med 7:23. https:\/\/doi.org\/10.4103\/2008-7802.174762","journal-title":"Int J Prev Med"},{"key":"4469_CR36","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/ptr.6361","volume":"33","author":"V Soleimani","year":"2019","unstructured":"Soleimani V, Delghandi PS, Moallem SA, Karimi G (2019) Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytotherapy Research\u202f: PTR 33:1627\u20131638. https:\/\/doi.org\/10.1002\/ptr.6361","journal-title":"Phytotherapy Research : PTR"},{"key":"4469_CR37","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.kint.2018.11.03026","volume":"95","author":"HG Sparrow","year":"2019","unstructured":"Sparrow HG, Swan JT, Moore LW, Gaber AO, Suki WN (2019) Disparate outcomes observed within Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury stage 1. Kidney Int 95:905\u2013913. https:\/\/doi.org\/10.1016\/j.kint.2018.11.03026","journal-title":"Kidney Int"},{"key":"4469_CR38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/antiox4010204","volume":"4","author":"PF Surai","year":"2015","unstructured":"Surai PF (2015) Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants (Basel) 4:204\u2013247. https:\/\/doi.org\/10.3390\/antiox4010204","journal-title":"Antioxidants (Basel)"},{"key":"4469_CR39","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3390\/jcm9041104","volume":"9","author":"C Thongprayoon","year":"2020","unstructured":"Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Torres-Ortiz A, Acharya P, Gonzalez-Suarez ML, Kaewput W, Bathini T, Cheungpasitporn W (2020) Diagnostics, risk factors, treatment and outcomes of acute kidney injury in a new paradigm. J Clin Med 9:1104","journal-title":"J Clin Med"},{"key":"4469_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/aac.01568-122","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57:734\u2013744. https:\/\/doi.org\/10.1128\/aac.01568-122","journal-title":"Antimicrob Agents Chemother"},{"key":"4469_CR41","doi-asserted-by":"publisher","first-page":"e1003969","DOI":"10.1371\/journal.pmed.1003969","volume":"19","author":"M Wainstein","year":"2022","unstructured":"Wainstein M, MacDonald S, Fryer D, Young K, Balan V, Begum H, Burrell A, Citarella BW, Cobb JP, Kelly S, Kennon K, Lee J, Merson L, Murthy S, Nichol A, Semple MG, Strudwick S, Webb SA, Rossignol P, Claure-Del Granado R, Shrapnel S (2022) Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: a multinational study using the ISARIC-WHO clinical characterisation protocol. PLoS Med 19:e1003969. https:\/\/doi.org\/10.1371\/journal.pmed.1003969","journal-title":"PLoS Med"},{"key":"4469_CR42","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1186\/s12882-023-03172-8","volume":"81","author":"Y Wang","year":"2015","unstructured":"Wang Y, Hougaard AB, Paulander W, Skibsted LH, Ingmer H, Andersen ML (2015) Catalase expression is modulated by vancomycin and ciprofloxacin and influences the formation of free radicals in Staphylococcus aureus cultures. Appl Environ Microbiol 81:6393\u20136398. https:\/\/doi.org\/10.1186\/s12882-023-03172-8","journal-title":"Appl Environ Microbiol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04469-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:02:56Z","timestamp":1771538576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04469-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4469"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04469-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the local Ethics Committee of Mashhad University of Medical Sciences (IR.MUMS.REC.1400.264) and was registered at the Iranian Registry of Clinical Trials (IRCT20200408046990N9, 2022\u201304-06). All participants signed written consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}